Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 19:13:886961.
doi: 10.3389/fendo.2022.886961. eCollection 2022.

TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis

Affiliations
Review

TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis

Jian Xu et al. Front Endocrinol (Lausanne). .

Abstract

TEMPI (telangiectasias, elevated erythropoietin level and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting) syndrome is a rare and newly defined multisystemic disease, which belongs to "monoclonal gammopathy of clinical significances". Due to its rarity, the etiology, pathogenesis, and clinical features of this disease remain largely unknown. Owing to its hidden and diverse clinical manifestations, missed diagnosis and misdiagnosis are common. In recent years, as more patients (including three fatal cases) were identified, some special clinical manifestations other than the typical pentad of TEMPI syndrome have been reported. Meanwhile, several studies attempting to identify the pathogenesis of TEMPI syndrome were conducted. In this review, we summarize the reported clinical characteristics of TEMPI syndrome and discuss the current and potential treatment options for patients with TEMPI syndrome, including those with relapsed/refractory disease. Furthermore, we provide an overview of current knowledge on the pathophysiology of TEMPI syndrome.

Keywords: TEMPI syndrome; clinical manifestations; monoclonal gammopathy of clinical significance; pathogenesis; plasma cell-directed treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Sykes D, Schroyens W, O’Connell C. The TEMPI Syndrome–a Novel Multisystem Disease. N Engl J Med (2011) 365(5):475–7. doi: 10.1056/NEJMc1106670 - DOI - PubMed
    1. Sykes D, O’Connell C, Schroyens W. The TEMPI Syndrome. Blood (2020) 135(15):1199–203. doi: 10.1182/blood.2019004216 - DOI - PubMed
    1. Schroyens W, O’Connell C, Sykes D. Complete and Partial Responses of the TEMPI Syndrome to Bortezomib. N Engl J Med (2012) 367(8):778–80. doi: 10.1056/NEJMc1205806 - DOI - PubMed
    1. Mohammadi F, Wolverson M, Bastani B. A New Case of TEMPI Syndrome. Clin Kidney J (2012) 5(6):556–8. doi: 10.1093/ckj/sfs139 - DOI - PMC - PubMed
    1. Jasim S, Mahmud G, Bastani B, Fesler M. Subcutaneous Bortezomib for Treatment of TEMPI Syndrome. Clin Lymphoma Myeloma Leuk (2014) 14(6):e221–3. doi: 10.1016/j.clml.2014.07.004 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources